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Antimicrobial Peptides
A complex immune system enables vertebrate animals to
resist challenges from potential pathogens. Some immune system components, such as antibodies and T-cells, show exquisite specificity. Others, like antimicrobial peptides (AMPs),2 act
more broadly. Most AMPs are small (1–5 kDa), positively
charged, and amphipathic. Two types of AMPs are pertinent to
this minireview: cathelicidins and defensins. Both have ancient
roots, with cathelicidins having been traced back to hagfish and
␤-defensins to bony fish.
Cathelicidins
These structurally diverse peptides share a conserved prodomain called “cathelin” (1). Whereas cattle and pigs express 10 or
more different cathelicidins, mice and humans express only
* This

is the third article in the Thematic Minireview Series on Circular
Proteins.
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2
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Defensins
In vertebrates, these peptides comprise three subfamilies
called ␣-, ␤, and -defensins. All of these defensins have six
conserved cysteines, three intramolecular disulfide bonds, a net
positive charge, and ␤-sheet regions. The cysteines in ␣- and
␤-defensins differ in their spacing and pairing (3), and some
␤-defensins (but no ␣-defensins) contain a short ␣-helical
region.
Other peptides have also been called defensins based on their
structural and functional similarities to those of vertebrates.
Plectasin, from the saprophytic fungus Pseudoplectania
nigrella, shows remarkable homology to the defensins of dragonflies (Aeschna cyanea) and mussels (Mytilus galloprovincialis), lineages that diverged over 1 billion years ago (4). It is possible (5), but unproven, that fungal defensins are ancestral to
vertebrate ␤-defensins.
The human genome contains ⬎30 different ␤-defensin
genes, and mice have even more (6). However, research has
focused mostly on human ␤-defensin-1–3, which are expressed
by epithelial cells throughout the body. Certain other human
and rodent ␤-defensins are expressed in localized regions of the
male genitourinary tract and participate in events related to
reproduction (7).
Polymorphonuclear neutrophils (PMNs) are white blood
cells that can ingest and kill intruding pathogens. PMNs from
cattle (8) and chickens (9) contain multiple ␤-defensins, but
primate PMNs contain ␣-defensins instead. The presence of
␣-defensins in basal mammals and marsupials indicates that
these genes arose before the groups diverged, some 130 million
years ago (10).

Human ␣-Defensins
Humans express six different ␣-defensin peptides. Three of
these, human neutrophil peptides (HNPs) 1–3, constitute 5–7%
of total PMN protein. The DEFA1 and DEFA3 genes for HNP-1
(Fig. 1a) and HNP-3 have duplicated, and extensive copy number polymorphism exists. Consequently, some people carry
four copies of both genes (i.e. two on each chromosome),
whereas others have 11 copies of both (11). Human PMNs also
have small amounts of another ␣-defensin, HNP-4, which is
identical to HNP-1–3 in only 11 of 29 –30 residues. Human
␣-defensin-5 and -6 are secreted primarily by Paneth cells in the
small intestine.
HNP-1 prepropeptides contain a 19-residue signal sequence,
a 45-residue anionic propiece, and a 30-residue defensin
domain (Fig. 1). Removing the N-terminal residue from either
HNP-1 or HNP-3 creates HNP-2, whose first and last residues
are both cysteines that are joined by a disulfide bond, a common
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-Defensins, the only cyclic peptides of animal origin, have
been isolated from the leukocytes of rhesus macaques and
baboons. Their biogenesis is unusual because each peptide is an
18-residue chimera formed by the head-to-tail splicing of nonapeptides derived from two separate precursors. -Defensins
have multiple arginines and a ladder-like tridisulfide array spanning their two antiparallel ␤-strands. Human -defensin genes
contain a premature stop codon that prevents effective translation of the needed precursors; consequently, these peptides are
not present in human leukocytes. Synthetic -defensins with
sequences that correspond to those encoded within the human
pseudogenes are called retrocyclins. Retrocyclin-1 inhibits the
cellular entry of HIV-1, HSV, and influenza A virus. The rhesus
-defensin RTD-1 protects mice from an experimental severe
acute respiratory syndrome coronavirus infection, and retrocyclin-1 protects mice from infection by Bacillus anthracis spores.
The small size, unique structure, and multiple host defense
activities of -defensins make them intriguing potential therapeutic agents.

one. Porcine protegrins are cathelicidins with many structural
similarities to -defensins (Fig. 1). These include having 18 residues, a ␤-hairpin backbone, intramolecular disulfides, and
multiple arginines. Unlike the -defensins, protegrins lack a
cyclic backbone, unless one is imparted in the laboratory (2).
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mode of cyclization. One more evolutionary event led to the
backbone cyclic peptides described below.

Rhesus -Defensins
Much of our knowledge about these peptides appeared in the
report describing rhesus -defensin-1 (RTD-1) (20). The
authors purified an extract of rhesus macaque PMNs and tested
its components for bactericidal activity against Escherichia coli,
a common urinary tract pathogen, and the clinically temperate
502A strain of Staphylococcus aureus. They found eight AMPs,
seven ␣-defensins, and one smaller (2082 Da) peptide. Biochemical characterization of the small AMP led to the cyclic
structure illustrated in Fig. 1. Further studies demonstrated
that this 18-residue peptide was heterodimeric, formed by the
fusion of two nine-residue peptide fragments. Each of its initial
monomers was the product of a mutated ␣-defensin gene containing a premature stop codon (Fig. 1b, red arrow) in its defensin domain. Because of the codon’s position, the initial defensin
domain products had only 12 residues and required proteolytic
removal of a C-terminal tripeptide to create a nonapeptide
“building block” with three cysteines, including one at its C
terminus (Fig. 1b). Two such nonapeptides were converted into
a -defensin by two peptide bonds that spliced them in a headto-tail manner.
Rhesus macaques have three -defensin (DEFT) genes that
encode different nonapeptides. For simplicity, we will call the
different nonapeptides A, B, and C. Because the nonapeptides
in a -defensin can be identical (AA, BB, and CC) or different
(AB, AC, and BC) (12, 13), two different DEFT genes can produce three different peptides (AA, AB, and AC), and three different DEFT genes can produce six (AA, BB, CC, AB, AC, and
BC). All six potential -defensin peptides exist in rhesus PMNs
AUGUST 3, 2012 • VOLUME 287 • NUMBER 32

(14), but their relative amounts differ greatly, with RTD-1 being
the most abundant. Because n different DEFT genes could produce (n/2)(n ⫹ 1) peptides (12), the four DEFT genes of olive
baboons (Papio anubis) could produce 10 different peptides.
Five of these were identified at the peptide level (15).

Human Retrocyclins
These humanized -defensins resulted from a combination
of cloning, peptide synthesis, and molecular archeology. One
decade before RTD-1 was described, Vladimir Kokryakov and
colleagues at the Institute for Experimental Medicine in St.
Petersburg, Russia, and UCLA discovered protegrins (PGs)
(Fig. 1d) in extracts of porcine PMNs (16). The peptide had
unusually potent and broad antimicrobial properties, and an
analog named IB367 (17) entered human trials as a topical agent
intended to prevent oral mucositis associated with cancer treatment. A phase III trial of IB367 failed (18), partly due to the
peptide’s inherent cytotoxicity, a property that might have been
mitigated by cyclizing its backbone (2), as shown in Fig. 1d.
The same Russian-UCLA group later found a small AMP in
rhesus macaque blood. Because its mass and composition
resembled those of PG-1, cDNA cloning studies were done to
identify it. Rhesus bone marrow expressed only one cathelicidin, but as it was too large (37 residues) and lacked cysteines, it
was unrelated to the rhesus PG-like peptide (19). Subsequently,
six rhesus ␣-defensin-like genes were cloned, including three
whose C-terminal defensin domains would have ended after
only 12 residues had been translated. The putative dodecapeptides were called “demidefensins,” but the investigators were
unable to figure out how 12 ⫹ 12 might equal 18. After the
epiphany (20), the investigators followed the advice of Efraim
Racker, a distinguished biochemist (1913–1991), who said, “It
JOURNAL OF BIOLOGICAL CHEMISTRY
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FIGURE 1. Panel a shows the layout of the prepropeptide of a human ␣-defensin, HNP-1, as well as the sequence (seq.) of its C-terminal defensin domain. The
red arrow represents a stop codon. Panel b shows the corresponding layout and sequences for RTD-1. An additional stop codon (red arrow) limits the initial
defensin domain peptides to 12 residues, three of which will be removed during subsequent post-translational processing. The mature cyclic RTD-1 peptide
is composed of two different nine-residue precursors. Panel c shows the human counterparts of RTD-1. The transcripts contain an additional stop codon in the
signal sequence domain. This mutation aborts translation of the -defensin peptide precursors. Panel d shows simplified structural diagrams of five structurally
related antimicrobial peptides. In these diagrams, arginines are red, lysines are orange, and cysteines are blue. Asterisks signify amidated C-terminal arginines.
Polyphemusin-2 was isolated from the white blood cells of the horseshoe crab Limulus polyphemus. It has impressive antimicrobial properties and is active
against HIV-1 (50, 51). The other four peptides are discussed in text.
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doesn’t matter if you fall down as long as you pick something up
from the floor when you get up.”
Although human PMNs lacked any -defensin peptides,
human bone marrow contained mRNA that closely resembled
the mRNA of rhesus -defensin precursors. However, the
human mRNA contained an additional stop codon in its signal
sequence, indicating its derivation from an expressed pseudogene. Although this mRNA seemed useless for in vivo -defensin production, it provided sequence information that allowed
the investigators to recreate the lost -defensin by solid-phase
peptide synthesis. They christened the resurrected peptide
“retrocyclin-1” (Fig. 1d), from “retro,” meaning backwards in
time, and “cyclin,” referring to its cyclic backbone.

Antitoxic Properties
Just as human ␣-defensins can inhibit various bacterial exotoxins (23), -defensins can do this as well. The susceptible
toxins include anthrax lethal factor (24) and cholesterol-dependent lytic toxins, such as listeriolysin O from Listeria monocytogenes and anthrolysin from Bacillus anthracis (25, 26). Listeriolysin O permits ingested Listeria to escape confinement
and destruction in the phagocytic vacuoles of macrophages by
entering the more congenial cytoplasmic space, where they can
replicate and hitchhike to adjoining cells. Inactivating listeriolysin traps Listeria in the vacuole and helps control the infection (25). Although the pathogenic role of anthrolysin is less
certain, similar events may take place with B. anthracis because
RC-1 not only prevents the germination of its spores (24), but
also facilitates their destruction by macrophages (27).

Activity against HIV-1
RC-1 has an impressive ability to protect human target cells
from infection by HIV-1 in vitro (28). It is hardly necessary to
explain why this effect could be important, so instead we will
explain its mechanism. The process whereby the AIDS virus
enters a cell usually involves gp120, a viral surface glycoprotein

27016 JOURNAL OF BIOLOGICAL CHEMISTRY

Mechanism of Anti-HIV Activity
RC-1 neither damaged target cells nor directly inactivated
the virus, so cytotoxic or virotoxic effects were unlikely mechanisms. RC-1 did inhibit the formation of proviral DNA, indicating that it acted early, most likely by preventing viral entry
(29). RC-1 was not effective against HIV-2 and simian immunodeficiency virus type 1, related retroviruses that infect blood
mononuclear cells or primary fibroblasts independently of
CXCR4 or CCR5 (30). Because RC-1 protected human CD4positive lymphocytes from infection by HIV-1 strains that used
either co-receptor, the investigators initially speculated that it
might bind gp120 or CD4.
Surface plasmon resonance experiments revealed that RC-1
bound both, with dissociation constants (Kd) of 35.4 nM for
gp120 and 31 nM for CD4. RC-1 also showed high affinity binding to galactosylceramide (Kd ⫽ 24.1 nM), a surface glycolipid
also implicated in HIV-1 binding. This high affinity binding of
RC-1 required both its cyclic backbone and intact disulfide
bonds. A cyclic analog of RC-1 whose three disulfide bonds
were reduced and alkylated bound gp120 and CD4 ineffectively,
as did a noncyclic analog that contained three disulfide bonds.
Neither analog protected cells from HIV-1 infection.
RC-1 also bound with high affinity to fetuin, an extensively
glycosylated protein in fetal calf serum, but showed much less
effective binding to bovine serum albumin or to nonglycosylated gp120. Experiments with glycosidase-treated fetuin,
gp120, and CD4 suggested that both O-linked and N-linked
sugars provided binding sites for gp120. In a panel of 18 retrocyclin variants, binding to immobilized gp120 and CD4 was
highly correlated to each other and to the ability to protect
human peripheral blood mononuclear cells from infection by
HIV-1. These experiments suggested that the ability of RC-1 to
bind carbohydrate-containing surface molecules was integrally
related to its ability to protect cells from HIV-1 infection.
To further elucidate the mechanism, fusion assays were done
using susceptible target cells and effector cells that expressed
envelope glycoproteins of HIV-1 (32). RC-1 completely blocked
fusion mediated by HIV-1 envelopes that used CXCR4 or
CCR5, but had little effect on cell fusion mediated by HIV-2 or
simian immunodeficiency virus envelope proteins. RC-1 inhibited HIV-1 envelope-mediated fusion without impairing the
lateral mobility of CD4. It also inhibited the fusion of CD4deficient cells with cells bearing CD4-independent HIV-1 envelopes. Thus, RC-1 could prevent HIV-1 entry without either
cross-linking membrane proteins or inhibiting gp120-CD4
interactions (32).
Timing studies indicated that RC-1 acted late in the HIV-1
fusion process, but before six-helix bundle formation (31).
Binding experiments showed that retrocyclin bound the ectodomain of gp41 with high affinity in a glycan-independent
manner and also that it bound selectively to the C-terminal
VOLUME 287 • NUMBER 32 • AUGUST 3, 2012
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Antimicrobial Properties
Retrocyclin-1 (RC-1) and RTD-1 (21) killed E. coli in the
same way as human ␣-defensins (22), by permeabilizing its
membranes. Rhesus -defensins were expressed in the PMNs
and monocytes of macaques and baboons, but more abundantly
in the former (16, 21). RTD-1 killed E. coli ML-35 in medium
with physiological concentrations of NaCl, Ca2⫹, or Mg2⫹ that
inhibited ␣-defensins. The antimicrobial effects of RTD-1–3
and PG-1 were tested against E. coli, S. aureus 502A, and Candida albicans (an opportunistic fungus) to determine the minimal microbicidal concentration (MMC), i.e. the peptide concentration that killed at least 99.9% of the organisms in a 2-h
incubation period in low salt medium. RTD-1 and RTD-2 had
MMCs of 1–2 g/ml against all three organisms. RTD-3 had
somewhat higher MMCs (1.5–3.0 g/ml), and PG-1 had lower
ones (0.3–1.0 g/ml). Addition of 154 mM NaCl to the medium
increased the MMCs of RTD-1–3 against S. aureus above 10
g/ml, without increasing the MMC of PG-1. Whereas PG-1
had significant cytotoxic and hemolytic properties, RTDs
caused little cytotoxicity, and even at 100 g/ml did not hemolyze human red blood cells.

(carbohydrates account for 55% of its mass) that engages two
receptors on surface of the target cell. One receptor is CD4, and
the second can be either CXCR4 or CCR5. Following this initial
binding, another viral surface glycoprotein, gp41, undergoes
conformational changes to form a six-helix bundle structure
that mediates viral entry.

MINIREVIEW: -Defensins
heptad repeat of gp41 (31). Other analyses revealed that RC-1
prevented six-helix bundle formation. This mode of action
resembles that of peptidic entry inhibitors containing portions
of the gp41 sequence (30) and enfuvirtide, a clinically used peptide agent that blocks HIV-1 entry. Most single site mutations
of the viral heptad repeat residues predicted to bind retrocyclin
decreased or abolished the intrinsic infectivity of HIV-1 (32,
33).
In another study, the anti-HIV-1 activity of RTD-1 was compared with those of human ␣-defensin HNP-1 and ␤-defensin.
All showed activity, but their mechanisms differed. All three
defensins decreased CXCR4 expression on the target cell surface, but only RTD-1 inhibited viral entry. HNP-1 and human
␤-defensin-2 inactivated the X4 and R5 strains of HIV-1, but
RTD-1 inactivated only strains that used the CXCR4 co-receptor (34).

Activity Versus Herpes Simplex Viruses
Twenty -defensins were tested in vitro to determine their
ability to prevent infection of cervical epithelial cells by HSV-1
and HSV-2 (38). RC-1, RC-2, and RTD-3 were all protective,
but only RC-2 did not require preincubation with the virus.
RC-2 bound HSV-2 glycoprotein B with a Kd of 13.3 nM and did
not bind deglycosylated HSV-2 glycoprotein B. Temperature
shift experiments indicated that RC-2 and human ␣-defensins
HNP-1–3 protected cells from HSV-2 by different mechanisms. RC-2 blocked HSV attachment, but HNP-1–3 had little
effect on binding, and they were effective if added later.
Structural Studies
The three-dimensional structures of RTD-1 and its open
chain analog were determined by two-dimensional NMR (39).
RTD-1 and the noncyclic analog had similar extended ␤-hairpin structures in water, with well defined flexible turns at one or
both ends. Their ␤-sheet strands showed some flexibility,
despite the three disulfide bonds that connected them. Unlike
more typical AMPs, RTD-1 lacked an amphiphilic character.
Some amide protons of RTD-1 that should have been solventAUGUST 3, 2012 • VOLUME 287 • NUMBER 32

Phylogeny
Among the world’s 7 billion people, might some human
groups have retained intact DEFT genes? Rather than testing
this directly, a phylogenetic study was performed (43), revealing
that humans and their closest ape relatives (gorillas, chimpanzees, and bonobos) all had -defensin genes with an identical
stop codon mutation in the signal sequence. In the orangutan,
six DEFT genes were intact, and one was defective. Only intact
DEFT genes were found in several Old World monkeys and in
the siamang (Hylobates syndactylus), a lesser ape. No DEFT
genes were found in DNA from six New World monkeys and
five prosimians. This evidence suggests that DEFT genes and
-defensins arose in Old World monkeys and that intact genes
lasted in our own lineage until it diverged from orangutans,
some 7.5 million years ago. These considerations make it
unlikely that any human populations express retrocyclins
spontaneously.
However, human cells can express -defensins when cultured with an aminoglycoside that enables the translation apparatus to misread and bypass the premature stop codon (44).
When human cells or cervicovaginal tissues were so treated in
vitro, they produced intact RC-1, showing that the trimming
and splicing steps needed to produce -defensins are available
(44). In addition to finding -defensin mRNA transcripts in
human bone marrow and spleen, smaller amounts were
detected in thymus, testis, and skeletal muscle (43). In contrast,
Northern blot analysis of RTD-1 expression in rhesus macaque
tissues demonstrated abundant transcripts only in bone marrow, but not in these other sites (3). Because different methods
were used in these studies, these interspecies differences may
be more apparent than actual.
Musings
Did humans lose -defensins because an ancestor was dealt
only the pseudogene cards from the gene deck? Were they
made redundant by the multiply duplicated ␣-defensin genes?
Although RTDs may be more potent than ␣-defensins, their
JOURNAL OF BIOLOGICAL CHEMISTRY
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Activity against Influenza A Virus
RC-1 neutralized influenza A virus (IAV) by impairing hemagglutinin-mediated viral entry (35) and by inducing viral
aggregation that enhanced ingestion of IAV by neutrophils
(36). Retrocyclin-2 (RC-2), which differs from RC-1 only by
having an additional arginine, was more effective than RC-1, as
was RC-101, which differs from RC-1 by having a single Argto-Lys substitution. RC-2 inhibited IAV infection by blocking
hemagglutinin-mediated membrane fusion. It could act late in
the fusion process, even after hemagglutinin-induced membrane hemifusion had occurred. Like RC-1, RC-2 is also a multivalent lectin, and it prevented IAV entry by creating a network
of cross-linked immobilized surface glycoproteins. RC-2 also
inhibited fusion mediated by Sindbis virus and baculovirus. The
former is an enveloped mosquito-borne virus, and the latter is
an insect pathogen (35). Although the therapeutic effects of
retrocyclins on IAV have yet to be tested in mammals, RC-2 was
reported to protect chicken embryos from infection by the
avian H5N1 strain of influenza A (37).

exposed in monomeric ␤-sheet structures had low temperature
coefficients, consistent with the presence of weak intermolecular hydrogen bonds. From biophysical studies with model
membranes, it was concluded that cyclic RTD-1 induced stabilized lipid peptide domains more efficiently than did its open
chain analog (40). In SDS micelles, the two-dimensional NMR
structure of RC-2 showed a well defined ␤-hairpin structure
braced by three disulfide bonds (41). Analytical ultracentrifugation and NMR data indicated that RC-2 self-associated and
formed trimers in a concentration-dependent manner. By
increasing the valence of retrocyclins, such self-association may
contribute to their high affinity binding to glycoproteins and
also enable them to cross-link these and other structures that
they bind. The orientation (tilt and rotation) of RC-2 molecules
within model membranes has also been studied by advanced
solid-state NMR techniques (42). Among the findings were that
RC-2 selectively disrupts the orientational order of anionic
membranes (which exist in most bacteria) while leaving intact
zwitterionic membranes (which are more representative of
mammalian membranes).

MINIREVIEW: -Defensins
mode of production is less efficient than the standard assembly
line production of ␣-defensins. “Quantity has a quality all its
own” was Stalin’s rationale for urging production of massive
numbers of low quality tanks to confront the more potent German tanks. This aphorism and the abundance of ␣-defensins in
human PMNs may be relevant to the absence of -defensins in
these cells, despite the many desirable qualities of these “lost”
peptides.

16.

17.

18.
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Possibilities
At present, a main focus has been developing -defensins as
topical microbicides to prevent sexually transmitted HIV-1 and
HSV infections (44 – 47). If their production can be scaled up
(48, 49), systemic applications will deserve testing to determine
how best to benefit from their impressive array of host defense
properties.
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